BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Osimertinib: trial readouts and FDA decisions
3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 6 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: AstraZeneca, CSPC Megalith Biopharmaceutical Co.,Ltd., Avistone Biotechnology Co., Ltd., Merus B.V., Shanghai JMT-Bio Inc., Klus Pharma Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P2 | CSPC Megalith Biopharmaceutical Co.,Ltd. | NCT07256509 A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous No | Non-Small Cell Lung Cancer | not yet recruiting | 120 |
| 2026-12-12 est. | P3 | CSPC Megalith Biopharmaceutical Co.,Ltd. | NCT07376382 A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC | NSCLC | not yet recruiting | 680 |
| 2027-01-11 est. | P3 | AstraZeneca AZN | NCT06417814 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EG | Metastatic Non-small Cell Lung Cancer | active not recruiting | 768 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-31 est. | P2 | Avistone Biotechnology Co., Ltd. | NCT06574347 Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. | Non-Small-Cell Lung Cancer | recruiting | 120 |
| 2026-10-01 | P1/P2 | Merus B.V. | NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | Non-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and | terminated | 194 |
| 2026-09-30 est. | P3 | Shanghai JMT-Bio Inc. | NCT06735391 A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non | Locally Advanced or Metastatic Non-squamous NSCLC; Harboring EGFR Sensitive Mutations NSCLC; Previou | recruiting | 516 |
| 2026-08-31 | P2 | Klus Pharma Inc. | NCT05816252 A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) | Non-small Cell Lung Cancer | active not recruiting | 356 |
| 2026-07-07 | P2 | AstraZeneca AZN | NCT06194448 To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations | Lung Cancer | active not recruiting | 76 |
| 2026-07-06 | P3 | AstraZeneca AZN | NCT05261399 Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treat | Carcinoma; Non-Small-Cell Lung | active not recruiting | 341 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.